The therapeutic effects of the VEGF decoy receptor fusion protein VEGF-Grab in chronic inflammatory diseases - PubMed
4 hours ago
- #Angiogenesis
- #Autoimmune Diseases
- #Therapeutic Protein
- Placental growth factor (PlGF) is crucial in autoimmune diseases like rheumatoid arthritis (RA) and multiple sclerosis (MS).
- VEGF-Grab, a VEGF decoy receptor fusion protein, binds and neutralizes VEGF and PlGF, showing therapeutic potential.
- Two forms of VEGF-Grab (PB101 and PB102) were engineered for enhanced binding affinity.
- In vitro assays demonstrated VEGF-Grab's effects on angiogenesis and immune-cell function.
- VEGF-Grab showed significant inhibitory effects in animal models of RA and MS.
- Combined treatment with IFN-β in the EAE model suggested enhanced efficacy.
- VEGF-Grab targets abnormal angiogenesis, cartilage invasion, and pathogenic Th17 cells.
- The study highlights VEGF-Grab's potential as a therapeutic candidate for RA and MS.
- Funding was provided by the National Research Foundation of Korea and biotech companies.